<DOC>
	<DOCNO>NCT00465985</DOCNO>
	<brief_summary>This study design provide efficacy safety data ACZ885 ( fully human anti-interleukin-1beta ( anti-IL-1beta ) monoclonal antibody ) administer injection subcutaneously ( s.c. ) patient Muckle-Wells Syndrome . Part I 8-week open-label , active treatment period identify ACZ885 responder . Part II double-blind , placebo-controlled period ass primarily efficacy ACZ885 compare placebo . Part III open-label , active treatment period patient receive ACZ885 every 8 week withdrawal completion Part II .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability ACZ885 Patients With Muckle-Wells Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cryopyrin-Associated Periodic Syndromes</mesh_term>
	<mesh_term>Cellulitis</mesh_term>
	<mesh_term>Eosinophilia</mesh_term>
	<criteria>Molecular diagnosis NALP3 mutation clinical picture resemble MuckleWells Syndrome . MuckleWells Syndrome patient participate CACZ885A2102 study , option participate study upon disease flare MuckleWells Syndrome patient require medical intervention either untreated treat ( i.e . ACZ885 , anakinra , investigational IL1 block therapy ) . History immunocompromised , include positive HIV screen test result . No live vaccination within 3 month prior start trial , trial , 3 month follow last dose . History significant medical condition , Investigator 's opinion would exclude patient participate trial . History recurrent and/or evidence active bacterial , fungal , viral infection . Positive tuberculin skin test 48 72 hour administration screen visit within 2 month prior screen visit , accord national guideline . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Muckle-Wells Syndrome</keyword>
	<keyword>child</keyword>
	<keyword>systemic autoinflammatory disease</keyword>
	<keyword>CIAS-1 gene</keyword>
	<keyword>NALP-3</keyword>
	<keyword>ACZ885</keyword>
	<keyword>human monoclonal anti-human interleukin-1beta ( IL-1beta )</keyword>
	<keyword>antibody</keyword>
	<keyword>autosomal dominant</keyword>
	<keyword>familial autoinflammatory syndrome</keyword>
</DOC>